Brief: Madrigal Pharmaceuticals Q3 EPS USD -4.92
31/10/2024 11:00
Oct 31 (Reuters) - Madrigal Pharmaceuticals Q3 operating income USD -116.304 million. * Q3 net income USD -106.964 million * Q3 operating expenses USD 178.479 million
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)